#USA #Epicured #cystic fibrosis #Anagram Therapeutics #Glen Cove

Epicured Partners with Anagram Therapeutics

Epicured Inc., a rising player in healthcare, has recently expanded its Life Sciences Division through a strategic partnership with Anagram Therapeutics. The collaboration aims to design and implement a nutrition program specifically tailored for individuals suffering from Exocrine Pancreatic Insufficiency (EPI), a condition often associated with Cystic Fibrosis.

In a notable clinical study presented at the North American Cystic Fibrosis Conference, Epicured crafted a specialized nutrition program to comply with the research protocol outlined by Anagram Therapeutics. EPI patients, who experience severe malabsorption, encounter significant challenges that diminish their quality of life and life expectancy.

Richard Bennett, CEO of Epicured, expressed the importance of this collaboration, emphasizing that the current treatments for EPI often fail to alleviate the complex gastrointestinal issues faced by patients. He stated, “Anagram Therapeutics' innovative strategy to tackle enzyme deficiencies is truly commendable. Epicured was established to assist those with gastrointestinal disorders, and it’s gratifying to elevate our efforts together in addressing the overwhelming suffering caused by EPI.”

Epicured leveraged its extensive expertise that combines clinical insights with culinary excellence, facilitating the creation of a high-quality nutrition solution that meets the specific requirements of Anagram’s study protocol. This partnership included the development of a customized menu, operational back-end support for the study, and strategies for participant engagement—critical components that ensured adherence and minimized dropout rates.

Danielle Gallotto, the Manager of Clinical Operations at Anagram, highlighted her appreciation of Epicured’s custom-designed nutrition plan, stating that it not only met the clinical demands of the study but also bolstered participant adherence. “The standardization of nutrition across a nationwide clinical trial was pivotal in achieving our research objectives,” she remarked.

The logistical challenge of delivering fresh, tailored meals to various locations in accordance with precise timelines was expertly managed by Epicured. The array of meals developed catered to the study participants’ macronutrient needs, as well as their diverse cultural preferences. Bennett elaborated, “For optimal outcomes, it was essential that our design enabled every participant to consume the same meal. Our focus was on ensuring equitable nutrition to expedite scientific progress for a demographic that has endured significant hardships.”

Overall, this innovative partnership between Epicured and Anagram Therapeutics showcases the critical role that customized nutrition plays in clinical research settings. As the Food is Medicine movement continues to gain momentum, collaborations like this illuminate the path towards integrating dietary solutions into healthcare, ultimately improving the well-being of many suffering from chronic conditions.

For more details about Epicured and their initiatives, you can visit their official website or follow their progress on social media platforms.